GlassScriptPhysician profile
Tracey E Coleman
NPI 1780936864
$4,495.64
in general payments reported to CMS, 2019-2025
22 companies · $975 in 2025
The $975 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,128 · 2022: $684 · 2023: $863 · 2024: $846 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,683.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $869.87 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $501.59 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $488.59 | 2021-2023 | |
| Abbott Laboratories | $335.34 | 2021-2025 | Cardiomems, Mitraclip, Absolute Pro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.55 | 2021-2025 | Jardiance |
| Abiomed | $252.59 | 2024-2025 | Impella |
| Pfizer INC. | $231.24 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $203.23 | 2021-2023 | Lifevest |
| Cvrx, INC. | $202.18 | 2024-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $144.09 | 2021-2025 | Onpattro |
| Impulse Dynamics (USA) INC. | $143.52 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $141.57 | 2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $133.03 | 2021-2024 | Xarelto |
| Scpharmaceuticals INC. | $129.67 | 2023-2025 | |
| Daiichi Sankyo INC. | $81.96 | 2023-2024 | Injectafer |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $74.20 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $63.15 | 2025 | |
| Vifor Pharma, INC. | $51.43 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.46 | 2023 | Camzyos |
| Recor Medical INC | $34.94 | 2025 | Paradise Ultrasound Renal Denervation System |
| Mannkind Corporation | $26.82 | 2025 | |
| Amgen INC. | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracey Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.